Logo image of OKUR

ONKURE THERAPEUTICS INC-A (OKUR) Stock Fundamental Analysis

NASDAQ:OKUR - Nasdaq - US68277Q1058 - Common Stock - Currency: USD

2.38  +0.07 (+3.03%)

Fundamental Rating

3

OKUR gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 553 industry peers in the Biotechnology industry. OKUR has a great financial health rating, but its profitability evaluates not so good. OKUR has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

OKUR had negative earnings in the past year.
In the past year OKUR has reported a negative cash flow from operations.
In the past 5 years OKUR always reported negative net income.
In the past 5 years OKUR always reported negative operating cash flow.
OKUR Yearly Net Income VS EBIT VS OCF VS FCFOKUR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M

1.2 Ratios

OKUR has a Return On Assets (-60.24%) which is in line with its industry peers.
OKUR has a Return On Equity of -66.38%. This is comparable to the rest of the industry: OKUR outperforms 56.96% of its industry peers.
Industry RankSector Rank
ROA -60.24%
ROE -66.38%
ROIC N/A
ROA(3y)-55.3%
ROA(5y)-45.4%
ROE(3y)-63.34%
ROE(5y)-51.1%
ROIC(3y)N/A
ROIC(5y)N/A
OKUR Yearly ROA, ROE, ROICOKUR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 -20 -40 -60 -80

1.3 Margins

OKUR does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
OKUR Yearly Profit, Operating, Gross MarginsOKUR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024

More info and screens

7

2. Health

2.1 Basic Checks

OKUR has more shares outstanding than it did 1 year ago.
The number of shares outstanding for OKUR has been reduced compared to 5 years ago.
There is no outstanding debt for OKUR. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
OKUR Yearly Shares OutstandingOKUR Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M
OKUR Yearly Total Debt VS Total AssetsOKUR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

Based on the Altman-Z score of -1.33, we must say that OKUR is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -1.33, OKUR is in line with its industry, outperforming 56.78% of the companies in the same industry.
OKUR has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -1.33
ROIC/WACCN/A
WACCN/A
OKUR Yearly LT Debt VS Equity VS FCFOKUR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 50M -50M 100M

2.3 Liquidity

OKUR has a Current Ratio of 11.17. This indicates that OKUR is financially healthy and has no problem in meeting its short term obligations.
OKUR has a Current ratio of 11.17. This is amongst the best in the industry. OKUR outperforms 81.74% of its industry peers.
OKUR has a Quick Ratio of 11.17. This indicates that OKUR is financially healthy and has no problem in meeting its short term obligations.
OKUR has a Quick ratio of 11.17. This is amongst the best in the industry. OKUR outperforms 81.92% of its industry peers.
Industry RankSector Rank
Current Ratio 11.17
Quick Ratio 11.17
OKUR Yearly Current Assets VS Current LiabilitesOKUR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 50M 100M 150M

More info and screens

1

3. Growth

3.1 Past

The earnings per share for OKUR have decreased strongly by -18.74% in the last year.
EPS 1Y (TTM)-18.74%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%52.4%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

OKUR is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 14.80% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y27.16%
EPS Next 2Y21.04%
EPS Next 3Y14.8%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
OKUR Yearly Revenue VS EstimatesOKUR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2025 2026 2027 200K 400K 600K
OKUR Yearly EPS VS EstimatesOKUR Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 -10 -20 -30

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

OKUR reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for OKUR. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
OKUR Price Earnings VS Forward Price EarningsOKUR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
OKUR Per share dataOKUR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 -4 6

4.3 Compensation for Growth

A more expensive valuation may be justified as OKUR's earnings are expected to grow with 14.80% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y21.04%
EPS Next 3Y14.8%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for OKUR!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ONKURE THERAPEUTICS INC-A

NASDAQ:OKUR (7/28/2025, 10:35:37 AM)

2.38

+0.07 (+3.03%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-06 2025-05-06/bmo
Earnings (Next)08-11 2025-08-11/bmo
Inst Owners86.46%
Inst Owner Change0.21%
Ins Owners1.48%
Ins Owner Change9.49%
Market Cap32.15M
Analysts85
Price Target32.64 (1271.43%)
Short Float %3.16%
Short Ratio1.99
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-30.71%
Min EPS beat(2)-81.5%
Max EPS beat(2)20.09%
EPS beat(4)1
Avg EPS beat(4)-30.74%
Min EPS beat(4)-81.5%
Max EPS beat(4)20.09%
EPS beat(8)3
Avg EPS beat(8)-15.09%
EPS beat(12)7
Avg EPS beat(12)-7.05%
EPS beat(16)9
Avg EPS beat(16)-4.61%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)5.1%
EPS NQ rev (3m)16.52%
EPS NY rev (1m)3.26%
EPS NY rev (3m)9.51%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.35
P/tB 0.35
EV/EBITDA N/A
EPS(TTM)-5.26
EYN/A
EPS(NY)-3.51
Fwd EYN/A
FCF(TTM)-3.27
FCFYN/A
OCF(TTM)-3.26
OCFYN/A
SpS0
BVpS6.71
TBVpS6.71
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -60.24%
ROE -66.38%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-55.3%
ROA(5y)-45.4%
ROE(3y)-63.34%
ROE(5y)-51.1%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 8.16%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 11.17
Quick Ratio 11.17
Altman-Z -1.33
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)175.58%
Cap/Depr(5y)195.35%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-18.74%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%52.4%
EPS Next Y27.16%
EPS Next 2Y21.04%
EPS Next 3Y14.8%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y19.19%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year16.4%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y7.75%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y6.96%
OCF growth 3YN/A
OCF growth 5YN/A